Updated:
Moleculin Biotech, Inc.
Groundbreaking Cancer Therapies | Moleculin Biotech, Inc. (NASDAQ: MBRX) is a clinical stage pharmaceutical company focused on the development of a broad...
Moleculin Biotech, Inc.
Groundbreaking Cancer Therapies | Moleculin Biotech, Inc. (NASDAQ: MBRX) is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of highly resistant tumors and viruses. The Company’s lead program, Annamycin is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.
General information
Firm type
other
Frequently asked questions
What is Moleculin Biotech's lead drug candidate?
Moleculin's lead candidate is Annamycin, a next-generation anthracycline designed to treat acute myeloid leukemia and soft tissue sarcoma. It is in Phase 2 clinical trials as of 2025 (per SEC filings and press releases).
Does Moleculin operate as a family office or an investment firm?
No. Moleculin Biotech is a publicly traded clinical-stage pharmaceutical company, listed on the Nasdaq. It does not manage third-party capital or function as a family office.
What therapeutic areas does Moleculin focus on?
Moleculin focuses on oncology, specifically drug-resistant cancers, and broad-spectrum antiviral therapies. Its pipeline includes Annamycin for AML and soft tissue sarcoma, plus WP1066 for brain tumors and pancreatic cancer.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on investors?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: